SPA
AXSM icon

Sherbrooke Park Advisers’s Axsome Therapeutics AXSM Stock Holding History

Sherbrooke Park Advisers’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-4,082
Closed -$345K – 615
2024
Q4 		$345K Buy
4,082
+734
+22% +$67.5K 0.11% 337
2024
Q3 		$301K Buy
+3,348
New +$292K 0.07% 568

Other funds holding AXSM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

Sherbrooke Park Advisers's AXSM Position: Q1 2025 in Review

Sherbrooke Park Advisers sold out of Axsome Therapeutics (AXSM) in Q1 2025, closing a stake of 4,082 shares — an estimated $345K sold.

Sherbrooke Park Advisers first reported a position in AXSM in Q3 2024 and held it in 2 quarters. The position peaked at $345K in Q4 2024. 353 funds tracked by Wall St. Rank hold AXSM as of Q1 2025.

  • Sherbrooke Park Advisers reported no remaining Axsome Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Sherbrooke Park Advisers sold 4,082 Axsome Therapeutics shares in Q1 2025, an estimated $345K.
  • Sherbrooke Park Advisers first reported a position in Axsome Therapeutics in Q3 2024 and held it in 2 quarters.
  • Sherbrooke Park Advisers's Axsome Therapeutics position peaked at $345K in Q4 2024.
  • 353 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q1 2025.

Based on Sherbrooke Park Advisers's 13F filing for Q1 2025, filed 15 May 2025.